PHP
ZYME icon

Parkman Healthcare Partners’s Zymeworks ZYME Stock Holding History

Parkman Healthcare Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-125,806
Closed -$667K – 97
2022
Q2 		$667K Buy
125,806
+6,520
+5% +$39.4K 0.25% 64
2022
Q1 		$781K Buy
119,286
+77,661
+187% +$692K 0.23% 71
2021
Q4 		$682K Buy
41,625
+11,625
+39% +$242K 0.15% 80
2021
Q3 		$871K Buy
+30,000
New +$997K 0.22% 68
2020
Q4 		– Sell
-85,000
Closed -$3.96M – 96
2020
Q3 		$3.96M Buy
+85,000
New +$2.92M 1.05% 40

Other funds holding ZYME

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Parkman Healthcare Partners's ZYME Position: Q3 2022 in Review

Parkman Healthcare Partners sold out of Zymeworks (ZYME) in Q3 2022, closing a stake of 125,806 shares — an estimated $667K sold.

Parkman Healthcare Partners first reported a position in ZYME in Q3 2020 and held it in 5 quarters. The position peaked at $3.96M in Q3 2020. 91 funds tracked by Wall St. Rank hold ZYME as of Q3 2022.

  • Parkman Healthcare Partners reported no remaining Zymeworks position as of Q3 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 125,806 Zymeworks shares in Q3 2022, an estimated $667K.
  • Parkman Healthcare Partners first reported a position in Zymeworks in Q3 2020 and held it in 5 quarters.
  • Parkman Healthcare Partners's Zymeworks position peaked at $3.96M in Q3 2020.
  • 91 funds tracked by Wall St. Rank held Zymeworks as of Q3 2022.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.